Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The table is being set for Big things in my opinion
My thoughts exactly
Yep,when this takes off it's gonna move real strong imo
That's my thought,this could be a multi bagger soon..imo
)) Nice !!
MUST READ,New Interview with Dr. Kendall !!-- >>
https://www.healthline.com/diabetesmine/david-kendall-from-lilly-to-Afrezza-inhaled-insulin#7
MNKD News out !
MNKD NEWS !! -- >>
MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension
MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it will initiate enrollment of patients in a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug (IND) application filed with the Food and Drug Administration (FDA). TreT is proposed as a drug-device combination product for the treatment of patients with pulmonary arterial hypertension (PAH), utilizing a small, portable, breath-powered inhaler that is intended to simplify drug dosing.
“We are excited to initiate enrollment of our Phase 1 clinical study and to extend the potential application of the Technosphere platform for unmet patient needs in a serious chronic disease such as PAH,” said Dr. David Kendall, Chief Medical Officer of MannKind. “We believe this study will allow for rapid evaluation of treprostonil dosing and therapeutic use in pulmonary arterial hypertension. If successful, this Phase 1 study will lead to registration studies in 2019.”
The primary objective of the Phase 1 clinical study is to investigate the safety, tolerability, and pharmacokinetics of TreT in healthy volunteers after dosing by oral inhalation. Secondary endpoints include the evaluation of systemic exposure and pharmacokinetics of TreT, including dose proportionality. For more information about the study, please visit ClinicalTrials.gov.
About Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a rare, chronic, progressive, and ultimately fatal disease. It is caused by the hardening and narrowing of the pulmonary arteries, which results in abnormally high blood pressure in these arteries, and leads, with time, to heart failure. The symptoms of PAH include shortness of breath, dizziness and fatigue, which grow more severe as the disease progresses. Patients with PAH have severe restrictions on their exercise capacity, reduced quality of life, and a shorter life expectancy. There is no cure for PAH; currently available treatments manage the symptoms only.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind's ability to enroll patients in clinical trials. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, difficulties in enrolling subjects in clinical trials, the results of clinical trials, the ability to obtain regulatory approvals, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2017 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com
Open at $5 tomorrow?
In FNJN @ $2.93
Added 2000 more MNKD at $2.71
Added 2000 more at $2.71
Again NO clue...imo
Look who the downgrade was from though..a joke imo
MNKD
Could be the Motha of all Squeezes coming....imo
I think so too,have a feeling Mike C. is holding a Ace up his sleeve...imo
I like it,he's got balls and is passionate about MNKD,that's why this is gonna be a homerun from here imo
Same...
Absolutely Agree...long and strong !
Same here and this is gonna be a multi bagger from here imo
New Team,watch and see...imo
Better cover your short...imo
Afreeza is gonna be a BLOCKBUSTER as in MNKD..watch and see....this company is gonna be a GAME CHANGER !!....all imo
Here's a post from the MNKD Proboards,good insight imo....
sayhey24
Postaholic
*****
I have listened to a lot of these calls for a lot of years and IMO this was the best I have heard. I think today marks a turning point for the company.
The biggest news I heard on the call was they found the 60+ studies which Al Mann did and Dr. Kendall not only read them but is putting a plan together to release them. That is huge.
While he did not say it I suspect these studies had a great deal to do with why Dr. Kendall came to MNKD. Al left no stone un-turned and concluded afrezza should be the standard of care for all T2s from the first day they are diagnosed.
Read more: http://mnkd.proboards.com/thread/9597/fourth-quarter-financial-results-conferen?page=7#ixzz58MMsDeFg
Someone said that time had run out on the CC
When you get a chance listen to the actual conference call on their website..I liked alot of what I heard.
MNKD
I listened to the call and I like what I heard,this company is making all the right moves now and gonna be Big time..I especially liked Dr. Kendall!!...but of course there is always the negative nellie spin
Look again ))
BOOM TIME closer and closer imo !!
Holding em tight for the Big Payoff !..imo
Nice.. gonna hold,just have a strange good feeling about the call after market...imo
MNKD $
Time to move back up,oversold yesterday ...imo
TGLO $$
I was thinking the same thing..I think Big things ahead for MNKD...Imo
MNKD..holding..have feeling they are gonna have some extra meat on the bone with Dr. Kendall on the call..imo
MNKD..getting started here...
Lol..yep...just hope he's buckled in for the move up..wouldn't want the poor guy to get whiplash imo
Thia is the future my man and from what I see it looks VERY BRIGHT !!..All imo
Low volume drop and your sick..imo
Dont be foolish and let certain posters scare you out of your shares,you can figure out their agenda pretty easily....all imo
Think MNKD gonna run hard this week imo